/C O R R E C T I O N -- Eli Lilly and Company/ – In the news release, New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Duloxetine, issued 11-Sep-2009 by Eli Lilly and Company over PR Newswire, the third paragraph, third sentence should read "A total of 18 patients in the study discontinued due to adverse events during theextension phase." The phrase "13 in the placebo-treated group and five in
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Duloxetine – Further Pain Reduction on Duloxetine Shown During Study's Extension PhaseNew data show patients with chronic low back pain on duloxetine hydrochloride (Cymbalta(R)) maintained reductions in pain for 41 weeks.(1) In patients who initially responded to duloxetine, this maintenance of pain reduction was accompanied by further reduction in
Study Showed New Episodes of Depression Delayed in People Taking Duloxetine – Longest controlled duloxetine trial to-date showed significant advantages over placeboDuloxetine hydrochloride (Cymbalta(R)/Xeristar(R)), administered at 60 to 120 mg once daily, delayed the onset of a new episode of depression in patients with recurrent depressive disorder, compared with placebo (p .05).Adverse EventsThe proportion of
European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia – The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a negative opinion on a Cymbalta(R) (duloxetine hydrochloride) application for the treatment of fibromyalgia. "Eli Lilly and Company and Boehringer Ingelheim are naturally disappointedby the CHMP's opinion," said James Russell,
Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder – Eli Lilly and Co (NYSE: LLY) and Boehringer Ingelheim have announced that the European Commission has approved the use of Cymbalta(R) (duloxetine) for the treatment of Generalised Anxiety Disorder (GAD). This approval -- the fourth for duloxetine in Europe -- was issued on 28 July following an initial positive opinion issued by the